Compositions for the treatment of sarcopenia or disuse atrophy

Patent metadata

Field	Value
Publication number	US-2021275639-A1
Application number	US-201917261314-A
Country	US
Kind code	A1
Filing date	Jul 19, 2019
Priority date	Jul 20, 2018
Publication date	Sep 9, 2021
Grant date	—

Abstract

The present invention relates to a substance that activates the GDF5 pathway, for use in a method for the treatment of age-related sarcopenia or disuse atrophy.

First claim

1 . A GDF5 pathway-activating substance for use in a method for the treatment or prevention of sarcopenia or disuse atrophy.

2 . A GDF5 pathway-activating substance for use in treating or preventing muscle weakness in a myopathy or neuromuscular disease, alone or in combination with a treatment of said myopathy or neuromuscular disease.

3 . The substance for use according to claim 1 , wherein the substance is selected from compounds that increase the activity of GDF5 or compounds that increase the expression of GDF5.

4 . The substance for use according to claim 1 , wherein the substance is recombinant human GDF5.

5 . The substance for use according to claim 1 , wherein the substance is recombinant human CaVβ1-E or a vector encoding human CaVβ1-E.

6 . The substance for use according to claim 1 , wherein the substance is administered to a subject aged 50 years or older, in particular 55 years or older, in particular 60 years or older, more particularly 65 years or older, even more particularly 70 years or older, such as 75 years or older or even 80 years or older.

7 . The substance for use according to claim 1 , wherein the substance is administered via the oral, nasal, intravascular, intramuscular, intraperitoneal route, transdermal or subcutaneous route.

8 . The substance for use according to claim 1 , wherein the substance is administered on a regular basis, such as on a monthly basis, in particular on a weekly basis, or more particularly on a daily basis.

9 . The substance for use according to claim 1 , wherein the treatment of sarcopenia results in an increase of muscle mass and/or function, an increase in physical performance or mobility, and/or an increase in muscle strength.

10 . A pharmaceutical composition comprising a GDF5 pathway-activating substance and a pharmaceutically acceptable carrier.

11 . The pharmaceutical composition according to claim 10 , wherein the substance is recombinant human GDF5.

12 . A GDF5 pathway-activating substance, for use as a medicament.

13 . The substance for use according to claim 12 , wherein said substance is recombinant human GDF5.

14 . A method for the diagnosis of sarcopenia in a subject, comprising determining the level of GDF5 in a biological sample of said subject.

Assignees

• Association Inst De Myologie
• Inst Nat Sante Rech Med
• Univ Sorbonne

Inventors

• Pietri-Rouxel France
• Falcone Sestina

Classifications

• A61P21/06

  Anabolic agents (androgens A61P5/26) · CPC title

• A61P21/00

  Drugs for disorders of the muscular or neuromuscular system · CPC title

• G01N2800/2878

  Muscular dystrophy · CPC title

• G01N2333/475

  Assays involving growth factors · CPC title

• G01N33/74

  involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors} · CPC title